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Peripheral Amino Acid Levels in Schizophrenia and 
Antipsychotic Treatment 
 
 
 
Abnormal levels of amino acids have been reported in patients with schizophrenia and have 
also been investigated as a biomarker to monitor antipsychotic treatment, however results 
have been inconsistent. The purpose of the present review is to summarize the evidence in 
the literature of whether amino acid levels can be a biomarker and predict the treatment out-
come in schizophrenia. The current review does not support amino acid concentration as a 
useful biomarker for monitoring antipsychotic response in patients with schizophrenia, al-
though there is evidence that high levels of serum homocysteine and glutamate might be con-
sidered as a trait marker for schizophrenia. This review has also highlighted a considerable 
dearth of studies, specifically of studies evaluating antipsychotic side-effects. 
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Introduction 
 
The synthesis of biogenic amines (dopamine, norepinephrine, serotonin and his-
tamine) is related to the uptake of their amino acid precursors tyrosine, tryptophan
and histidine.
1 The levels of these substrates in the central nervous system (CNS)
are influenced by the blood concentration of valine, leucine, isoleucine, and pheny-
lalanine, which have affinity for the same carriers of tyrosine and tryptophan to cross
the blood-brain barrier.
2 Other amino acids such as glycine, serine, glutamic acid and
aspartic acid function as neurotransmitters in the brain and are involved in neuronal
development.
3 A chemical imbalance of these neurotransmitters have been postulated
in the pathophysiology of schizophrenia. Thus, changes in amino acid plasma con-
centrations might affect the susceptibility to psychotic disorders and influence their
treatment outcome. 
According to this hypothesis, many researchers have monitored peripheral amino
acid concentrations in patients with schizophrenia during the antipsychotic treatment.
However, the changes in the serum amino acid concentrations were not replicated con-
sistently across studies, and different investigators concluded that further work is
required to better understand the relationship between the level of circulating amino 
acids and schizophrenia as well as to clarify its possible role in both the physiopatholo-
gy of psychotic disorders and the response to neuroleptics and atypical antipsychotics.
The aim of this review is to summarize the evidence for the correlation between the
levels of amino acids present in the blood and vulnerability for schizophrenia. Further-
more we reviewed the articles where the amino acid levels have been investigated as
antipsychotic treatment predictors. 
Medline was used to select appropriate papers that investigated amino acids in 
schizophrenia and antipsychotic treatment by matching the word schizophrenia and
antipsychotics with the names of twenty proteinogenic amino acids. In addition, the 
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following terms were employed: taurine, ornitine, citrulline 
and homocysteine. The abstracts of all studies generated 
by this searches were read by the first author to select ap-
propriate studies which met the following inclusion crite-
ria: i) only original research and published journal articles 
were included in the review; ii) the research must include 
the serum or plasma measurement of at least one amino 
acid in a sample of schizophrenia or psychotic subjects; 
iii) the study must have been written in English. 
 
L-tyrosine 
 
L-tyrosine is a non essential aromatic amino acid. Our 
group
4 found higher concentration of tyrosine without any 
change in the tyrosine/large neutral amino acid ratio in 
the serum of schizophrenia patients treated with cloza-
pine. This amino acid is the precursor of dopamine, nor-
epinephrine and epinephrine; therefore the lower concen-
tration of tyrosine could be a peripheral marker of the 
hyperdopaminergic condition hypothesized to explain psy-
chosis.
5 
 
L-tryptophan 
  
L-tryptophan is an essential amino acid and in several 
studies, researchers found lower concentration of trypto-
phan and a reduced tryptophan/large neutral amino acid 
(amino acids that compete with tryptophan for the up-
take) ratio in the serum of schizophrenia patients. For ex-
ample, Rao and colleagues
6 and Tortorella and collea-
gues
7 found lower levels of tryptophan in schizophrenia 
that can result in lower neuronal uptake of tryptophan, 
which may in turn produce lower serotonin levels in the 
CNS of patients with schizophrenia. 
L-tryptophan is the precursor of serotonin therefore 
the opposite variation of this amino acid and tyrosine in 
schizophrenia could be a trait-marker of the chemical 
imbalance of dopaminergic and serotonergic transmission 
postulated in schizophrenia.
5 It is also interesting that dur-
ing the clozapine treatment our group observed a signifi-
cant increase of the tryptophan level in patients with schi-
zophrenia, even though the level was still significantly 
lower than controls after 12 weeks of clozapine therapy. 
Similarly Alfredsson and colleagues
8 found an increase 
of tryptophan correlated to the improvement during the 
early part of the treatment. 
 
L-serine 
 
Among the conditionally essential amino acids, L-se-
rine is the most studied in schizophrenia for its role as co-
transmitter, regulating the N-methyl-D-aspartate (NMDA) 
glutamate receptors. Several studies have shown that there 
are high levels of serine in patients with schizophrenia as 
a trait marker rather than a state marker.
9 Waziri
10 reported 
that serine is increased in both the serum and the brain of 
individuals affected by schizophrenia and suggested a po-
ssible role of serine in the pathophysiology of schizophr-
enia. Macciardi and colleagues have replicated these re-
sults,
11 whereas other groups have reported
6,12,13 normal 
level of serine in the plasma. 
In contrast, by the mean of high pressure liquid chro-
matography we reported
4 that serine levels were lower 
in drug-free schizophrenics and no change were shown 
in serine levels during the chronic antipsychotic adminis-
tration even though there was a significant improvement 
of psychotic symptoms. 
It is possible that the inconsistency between this result 
and the results in other studies mentioned above is due 
to the clinical feature of the Italian sample that consisted 
in resistant schizophrenics according the Kane’s criteria.
14 
In fact, the long-lasting treatment with typical antipsychot-
ics in resistant subjects might induce a permanent decrease 
of serine levels in the blood, not sensitive to the wash-
out or the switch to clozapine. It is also interesting that 
Waziri and colleagues
10 reported a decreasing effect of 
neuroleptics on serine concentrations in subjects with psy-
chosis. In addition, inconsistent evidence among studies may 
account for the different methods used such as the mea-
surement technique, time of blood draw, dietary intake and 
genetic difference in the studied populations may account for 
the controversial evidence. Among these biasing factors, 
the diet could be the most important confounder. In fact L-
threonine free diet reduced the concentration of glutamic 
and aspartic acids in the nucleus accumbens of rat.
15 
 
L-glutamine 
 
L-glutamine is a non-essential amino acid. Alfredsson 
and colleagues
16 did not find any change in the serum glu-
tamine level of acutely psychotic patients compared to 
healthy volunteers. However, later the same group showed 
that high level of glutamine seems to predict the failure 
of sulpiride treatment
8 and a significant negative corre-
lation was shown between glutamine level and clinical 
response to sulpiride. 
 
L-asparagine 
 
L-asparagine is a non essential amino acids. The level 
of asparagine was found to be lower in subjects with 
schizophrenia (after wash-out) than in matched controls 
in our previous report.
4 However, no correlation was 
found between L-asparagine level and clozapine respon- 
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se.
4 One case report found extremely high level of as-
paragine in schizophrenia-like psychosis
17; however the 
metabolic correction of the hyperasparaginemia did not 
improve psychotic symptoms.
17 Consistently Rao et al.
6 
found higher levels of asparagine in drug-free patients 
with schizophrenia than in healthy controls. 
 
L-glutamate 
 
Glutamate is a non essential amino acid but it is the 
most important excitatory amino acid in the CNS. Our 
group
4 found that glutamate was elevated in our sample 
of 11 subjects with schizophrenia even though Alfredsson 
and colleagues
18 were unable to show any difference be-
tween schizophrenics and healthy volunteers. Our finding is 
consistent with Macciardi and colleagues who detected 
higher concentrations of glutamate in the serum of schiz-
ophrenia patients.
11 Tomiya
19 was able to show elevated 
serum level of glutamate only in male subjects with schiz-
ophrenia but not in females. 
Among studies that have suggested that different levels 
of glutamate can be useful predictor for antipsychotic treat-
ment, Tortorella and colleagues
4 found that clozapine 
lowered, but was unable to normalize, the glutamate le-
vel. In contrast, Evins and colleagues
20 found that the ch-
ronic treatment with clozapine produces increment of 
the glutamate in the blood. Furthermore Alfredsson and 
colleagues
8 found that glutamate was higher in non-res-
ponders to sulpiride and that during the treatment the level 
of glutamate increased consistently with the clinical im-
provement. More recently Goff and colleagues
21 found 
that Olanzapine treatment increases serum glutamate levels 
in patients previously treated with neuroleptics; finally, Mae-
shima and colleagues
22 found that increment of glutamate is 
associated with the remission stage after antipsychotic treat-
ment. The conflicting outcomes can be a result of the length 
of the follow-up significantly longer in the Evins’ study. 
Finally, it is possible that the lengthy storage of the samples 
can produce artefacts in the glutamate detection.
16 
The glutamatergic hypothesis of schizophrenia
7 pos-
tulates that the brain level of glutamate is lower in the 
brain of schizophrenic subjects and that antipsychotics 
operate as enhancers of the glutamatergic neurotransmis-
sion. However glutamate is not an essential amino acid; 
in fact it is actively synthesized in the CNS
3 therefore 
the peripheral level does not reflect the amount of gluta-
mate in the brain. More recently this lack of consistency 
between central glutamate and plasma glutamate has been 
confirmed by Goff et al.
21 and Shulman et al.
23 who 
showed that the peripheral glutamate does not correlate 
with the medial prefrontal cortical glutamate measured 
using the high-field strength proton magnetic resonance 
spectroscopy. However other studies have described a po-
sitive correlation between the level of glutamate in the 
cerebrospinal fluid and the serum.
16,24 
 
L-aspartate 
 
Aspartate is a non-essential amino acid. We found that 
aspartate was elevated in our sample of resistant schizo-
phrenics after antipsychotic wash-out.
4 Conversely, schiz-
ophrenic subjects switched to clozapine had no change 
after 12 weeks of treatment. Therefore, according to our 
data, aspartate and glutamate might be differently affected 
by the antipsychotic treatment. However, Evins et al.
20 
found that clozapine treatment increased the basal aspar-
tate serum level. 
 
Glycine 
 
Glycine is a non-essential amino acid and a inhibitory 
neurotransmitter; it plays also a role in the regulation of 
NMDA receptors. Higher concentrations of glycine were 
detected in the serum of schizophrenia patients compared 
to controls in some studies.
11,25 However, Carl and collea-
gues,
13 did not report any significant difference between 
schizophrenics and controls in terms of glycine level. Ac-
cording to Carl and colleagues
13 we were unable to find 
any relationship between glycine and schizophrenia or 
clozapine administration.
4 
 
L-proline 
 
Proline is considered a conditionally essential amino 
acid. Jaquet et al.
26 showed that moderate hyperprolinemia 
is a risk factor for schizophrenia and the serum proline 
levels are controlled by the enzyme proline dehydrogenase 
(PRODH). Furthermore Raux and colleagues
27 found that 
subjects with velo-cardio-facial syndrome (VCFS), a con-
dition that is often associated with schizophrenia, showed 
high levels of proline. It has been reported that 50% of the 
patients with VCFS are hyperprolinemic,
28 and that 12 to 
30%
29-31 of them have psychosis. 
 
L-alanine 
 
Alanine levels in schizophrenia have been poorly in-
vestigated. We did not find association between L-alanine 
and schizophrenia but we observed a reduction of this 
amino acid during a 12 weeks clozapine treatment. 
 
L-isoleucine 
 
L-isoleucine is one of the eight amino acids (phenyal- 
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alnine, valine, threonine, tryptophan, isoleucine, methio-
nine, leucine, and lysine) that are considered essential for 
humans and it is also considered a large neutral amino 
acid competing with tryptophan and tyrosine for the trans-
porter across the blood brain barrier. This amino acid is 
a branched chain amino acid and in our previous work
4 
we found that the serum level of isoleucine was higher 
than in schizophrenia subjects compared to healthy con-
trols. Higher levels of isoleucine in schizophrenia were 
found by Bjerkensedt et al.,
32 too. However there is no 
correlation between isoleucine level and antipsychotic 
treatment. 
 
L-phenylalanine 
 
L-phenylalanine is an aromatic amino acid. We did not 
find any significant difference in the level of phenyalanine 
when we compared schizophrenia individuals to controls. 
Furthermore the phenylalanine did not correlate with an-
tipsychotic treatments. However Wei et al.
33 found an im-
balance of the tyrosine-phenylalanine ratio in early onset 
patients with schizophrenia. 
 
L-leucine 
 
We found no variation in basal serum L-leucine asso-
ciated either with schizophrenia or antipsychotics. How-
ever Reveley et al.
34 found significantly higher levels of 
leucine in the cerebrospinal fluid (CSF) of schizophre-
nic patients. 
We found that valine is not associated with schizoph-
renia. In contrast, Bjerkenstedt
32 found higher concentra-
tions of valine in unmedicated schizophrenia subjects 
compared to healthy controls. 
 
L-histidine 
 
In our previous work,
4 we found that the serum levels 
of L-histidine was higher in schizophrenia subjects com-
pared to healthy controls. Our results were in agreement 
with Carl and colleagues
13 who found that hystidine and 
other basic amino acids tended toward higher level in 
schizophrenia. 
 
L-arginine 
 
L-ariginine is part of the urea cycle amino acid group. 
We did not find any correlation between the concentra-
tion of arginine and schizophrenia status or response to 
clozapine. However Carl et al.
13 found a trend for higher 
level of arginine and other basic amino acids in schizo-
phrenia. 
L-lysine 
 
Lysine is an essential amino acid. Bjerkenstedt
5 found that 
lysine is higher in the plasma of drug-free schizophrenics. 
 
L-threonine 
 
L-threonine levels in schizophrenia have been poorly 
investigated. In our previous work, we found that L-
threonine is associated neither with schizophrenia nor 
with clozapine response.
4 
 
L-methionine 
 
Baseline Methionine was found to be lower in non-
responders patients under atypical antipsychotic treat-
ment.
35 Furthermore Bjerkenstedt and colleague
32 found 
higher methionine plasma concentrations in unmedicated 
schizophrenics. Finally Fekkes at al.
36 found that the ratio 
of taurine and serine-methionine product was a useful 
diagnostic tool for acute psychosis. 
 
L-cysteine 
 
We did not quantify L-cysteine in our sample. However 
Rao et al.
6 found that this sulphur amino acid concen-
tration is lower in drug-free schizophrenics. 
 
Homocysteine 
 
Homocysteine is a non proteinogenic sulphur amino 
acid. A recent meta-analysis including 812 cases and 
2,113 controls showed that higher levels of this amino 
acid are associated with schizophrenia.
37 
 
Ornithine 
 
Ornithine is an urea cycle amino acid. Tomiya et al.
19 
found that ornithine serum level is positively correlated 
with the length of illness. Furthermore in a case report 
Perry et al.
17 found that ornithine were irregularly high 
in fasting plasma of an acute psychotic subject. 
 
Citrulline 
 
Citrulline is classified as an urea cycle amino acid and 
it was found higher in drug-free schizophrenics by Rao 
et al.
6 
 
Taurine 
 
Taurine is an inhibitory neurotransmitter and was found  
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significantly higher in drug-free schizophrenic patients.
32 
Taurine level in schizophrenia has been investigated by 
few researchers. 
 
Conclusions 
 
The majority of the published papers reviewed, have 
examined amino acid plasma levels in the context of the 
dopaminergic, serotonergic and glutamatergic hypothesis 
of schizophrenia. 
We have reviewed papers where amino-acid levels in 
schizophrenia patients have been compared to matched 
controls and manuscripts where amino acid levels have 
been used as predictors of treatment response. 
Few early studies have employed the Structured Clinical 
Interview for DSM-IV (SCID)
38 for diagnosing schizoph-
renia. Different rating scales have been utilized for asse-
ssing antipsychotic response. Consequently this hinders 
comparison between studies. 
Most of the studies including our work,
4 have employed 
the high-performance liguid chromatographic (HPLC) met-
hod, however few studies have employed gas chromatogra-
phy or ion exchange chromatography, underlying that there 
is not standard method for quantifying plasma amino acids. 
No working definition except for proline levels has been 
given as cut-off for defining an abnormal level. Previous 
research has not highlighted amino acid level differences 
between male and female, although Tomiya
19 found sex 
differences in glutamate plasma levels. 
With few exceptions, most of the studies reported he-
rein found high glutamate and homocysteine plasma levels 
associated with schizophrenia. However these two indi-
cators were rarely employed simultaneously. 
Finally, it seems that few investigators have focused 
on the levels of amino acids and antipsychotic side-ef-
fects. However since there is new evidence that atypical 
antipsychotics produce metabolic changes, the serum ami-
no-acid pattern might be an interesting tool to monitor 
metabolic side effects. 
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